Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer

Journal of Clinical Gastroenterology

Volumn 23, Issue 4, 1996, Pages 269-274

  Messori, Andrea ^a,b   Bonistalli, Lucia ^a   Costantini, Monya ^a   Trallori, Giacomo ^b   Tendi, Enrico ^a  

^a Pharmaceutical Service   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Adjuvant chemotherapy; Coldrectal cancer; Cost effectiveness analysis; Intraportal administration; Pharmacoeconomics

Indexed keywords

FLUOROURACIL; HEPARIN; LEVAMISOLE; MITOMYCIN;

AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ITALY; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; PORTAL VEIN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; ECONOMICS, PHARMACEUTICAL; FLUOROURACIL; HEPARIN; HUMANS; LEVAMISOLE; MITOMYCINS; PORTAL SYSTEM; SURVIVAL RATE;

EID: 0029773765     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199612000-00006     Document Type: Article

References (16)

1. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.
2. Mark DB. Economic analysis methods and end-points. In: Califf RM, Mark DB, Wagner B, eds. Acute coronary care in the thrombolytic era. St. Louis: Mosby, 1995:167-82.
3. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha2B treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995;122:664-75.
4. Lee ET. Statistical methods for survival data analysis. Belmont, CA: Lifetime Learning, 1980.
5. Varoli G. Matematica finanziaria. Bologna: Patron, 1990.
6. Messori A, Becagli P, Trippoli S, Tendi E. Cost-effectiveness of adjuvant chemotherapy with cyclophosphamide + methotrexate + fluorouracil in patients with node-positive breast cancer. Eur J Clin Pharmacol 1996;51 (in press).
7. Messori A. Trends, new developments and pharmacoeconomics. EHP 1996;2:124-7.
8. Messori A. Nuove tecniche di metanalisi e farmacoeconomia. Presented at the National Symposium Metodologie per la Clinica (Associazione Italiana Gastroenterologi Ospedalieri and the Associazione Italiana di Epidemiologia), Montecatini Terme, January 18-19, 1996.
9. Swiss Group for Clinical Cancer Research (SAKK). Long-term results of a single course of adjuvant intraportal chemotherapy for colorectal cancer. Lancet 1995;345:349-53.
10. Uyl-de Groot CA, Hagenbeek A, Verdonk LF, Lowenberg B, Rutten FFH. Cost-effectiveness of ABMT in comparison with CHOP chemotherapy in patients with intermediate- and high-grade malignant non-Hodgkin's lymphoma (NHL). Bone Marrow Transplant 1995;16:463-70.
11. Robinson R. Cost-effectiveness analysis. BMJ 1993;307:793-5.
12. Rougier Ph, Nordlinger B. Large-scale trial for adjuvant treatment in high-risk resected colorectal cancer. Ann Oncol 1993; 4:821-8.
13. Mulchahy HE, Farthing MJG. Adjuvant intraportal chemotherapy for colorectal cancer [Letter]. Lancet 1995;345:1184.
14. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economic returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994;86:424-30.
15. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of Stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-6.
16. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981;9:503-12.